Login to Your Account



Other News To Note


Friday, February 3, 2012
• Compugen Ltd., of Tel Aviv, Israel, reported findings on the potential of CGEN-15001T, a membrane protein, as a therapeutic target for multiple cancers using monoclonal antibody (mAb) therapy. The results indicated that CGEN-15001T is expressed on numerous types of cancer, including carcinomas, sarcomas, melanoma and hematological cancers, as well as on immune cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription